Publications by authors named "Bruce Morimoto"

Claim this Profile
M
Modeling digestion, absorption, and ketogenesis after administration of tricaprilin formulations to humans.
Zhuoxuan Li, Gisela Ramirez, Rushi Tang, Cheong Kin Xian Paul, Murali Nair, Bruce Morimoto

Eur J Pharm Biopharm· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer's Disease.
Samuel T Henderson, Bruce H Morimoto, Jeffrey L Cummings, Martin R Farlow, Judith Walker

J Alzheimers Dis· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translatability of the S7A core battery respiratory safety pharmacology studies: Preclinical respiratory and related clinical adverse events.
Sabina Paglialunga, Bruce H Morimoto, Matthew Clark, Gregory S Friedrichs

J Pharmacol Toxicol Methods· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics in Rat of P8, a Peptide Drug Candidate for the Treatment of Alzheimer's Disease: Stability and Delivery to the Brain.
Nazneen N Dewji, Marc R Azar, Leah R Hanson, William H Frey Ii, Bruce H Morimoto

J Alzheimers Dis Rep· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tracking the Sugar Rush: Incorporating Continuous Glucose Monitoring Into Multisite Early Clinical Research With Type 2 Diabetes Subjects.
Sabina Paglialunga, Bruce H Morimoto, Amparo de la Peña, Caroline Fortier

Clin Pharmacol Drug Dev· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic peptides for CNS indications: Progress and challenges.
Bruce H Morimoto

Bioorg Med Chem· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating cardiac risk: exposure response analysis in early clinical drug development.
Julie Grenier, Sabina Paglialunga, Bruce H Morimoto, Robert M Lester

Drug Healthc Patient Saf· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.
Sabina Paglialunga, Elliot Offman, Nita Ichhpurani, Thomas C Marbury, Bruce H Morimoto

Expert Rev Clin Pharmacol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials.
Jee Bang, Iryna V Lobach, Anthony E Lang, Murray Grossman, David S Knopman, Bruce H Morimoto

Parkinsonism Relat Disord· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Pharmacology in Drug Discovery and Development.
Bruce H Morimoto, Erin Castelloe, Anthony W Fox

Handb Exp Pharmacol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intranasal NAP (davunetide) decreases tau hyperphosphorylation and moderately improves behavioral deficits in mice overexpressing α-synuclein.
Iddo Magen, Regina Ostritsky, Franziska Richter, Chunni Zhu, Sheila M Fleming, Bruce H Morimoto

Pharmacol Res Perspect· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.
Adam L Boxer, Anthony E Lang, Murray Grossman, David S Knopman, Bruce L Miller, Bruce H Morimoto

Lancet Neurol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A double-blind, placebo-controlled, ascending-dose, randomized study to evaluate the safety, tolerability and effects on cognition of AL-108 after 12 weeks of intranasal administration in subjects with mild cognitive impairment.
Bruce H Morimoto, Don Schmechel, Joe Hirman, Andrew Blackwell, Julian Keith

Dement Geriatr Cogn Disord· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases.
Bruce H Morimoto, Anthony W Fox, Alistair J Stewart, Michael Gold

Expert Rev Clin Pharmacol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug development of intranasally delivered peptides.
Catherine Campbell, Bruce H Morimoto, Daniela Nenciu, Anthony W Fox

Ther Deliv· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.
Michael Gold, Stefan Lorenzl, Alistair J Stewart, Bruce H Morimoto, David R Williams

Neuropsychiatr Dis Treat· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
Sheila M Fleming, Caitlin K Mulligan, Franziska Richter, Farzad Mortazavi, Vincent Lemesre, Bruce Morimoto

Mol Cell Neurosci· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revision of the criteria for Alzheimer’s disease: A symposium.
Steven T DeKosky, Maria C Carrillo, Creighton Phelps, David Knopman, Ronald C Petersen, Bruce H Morimoto

Alzheimers Dement· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Development for Neurodegenerative Diseases--Second Annual marcus evans Conference. Advances in drug development for NDD and expediting discovery through novel compounds and sound clinical trials.
Bruce Morimoto

IDrugs· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addressing Alzheimer's disease tangles: from NAP to AL-108.
Illana Gozes, Alistair Stewart, Bruce Morimoto, Anthony Fox, Karole Sutherland

Curr Alzheimer Res· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
Bruce Morimoto

IDrugs· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EuroTIDES 2008--Informa Life Sciences' Ninth Annual Conference. Oligonucleotides, RNAi and peptides for the drug development and manufacturing industry.
Bruce Morimoto

IDrugs· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Looking for novel ways to treat the hallmarks of Alzheimer's disease.
Alistair J Stewart, Anthony Fox, Bruce H Morimoto, Illana Gozes

Expert Opin Investig Drugs· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
Illana Gozes, Bruce H Morimoto, Jacqueline Tiong, Anthony Fox, Karole Sutherland

CNS Drug Rev· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spectroelectrochemical Characterization of Substituted Cobalt Nitrosyl Porphyrins.
Abhay D. Kini, John Washington, Clifford P. Kubiak, Bruce H. Morimoto

Inorg Chem· November 1996

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis